We examined the epigenetic and transcriptomic landscapes associated with ASXL1 variants in BOS and AML, diseases with different clinical manifestations - BOS as a congenital disorder characterized by developmental delays and multiple malformations, and AML as a bone marrow malignancy - and identified several shared features. Here, ASXL1 is linked to acute myeloid leukemia.